| Astron Corporation Limited (ATR) ORDINARY FULLY PAID |
Materials |
$254 |
Bankable Feasibility Study - Donald Project Phase 1
|
31 Mar 2026 8:23AM |
$0.625 |
$0.590 |
fallen by
5.60%
|
|
ATR - Price-sensitive ASX Announcement
Full Release
Key Points
- Astron has completed a Bankable Feasibility Study (BFS) for Phase 1 of the Donald Project.
- Phase 1 of the Donald Project is expected to deliver robust economics with a pre-tax real NPV8 of $759 million and a post-tax IRR of 15.6%.
- The project is forecast to generate $3.3 billion of free-cash flows over its approximately 40-year life.
- The estimated capital expenditure for Phase 1 is $450.4 million, with a target 55% gearing ratio for funding.
- The BFS confirms that the project will deliver rare earth element concentrate containing light and heavy rare earths.
- Negotiations with potential financiers are advanced for a project financing package of up to $300 million.
- Key project metrics include ore processing throughput of 7.5 Mtpa and a life of mine of approximately 39.5 years.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SiteMinder Limited (SDR) ORDINARY FULLY PAID |
Information Technology |
$1,090 |
Appendix 3Y - S Lawson
|
31 Mar 2026 8:23AM |
$2.710 |
$3.850 |
risen by
42.07%
|
|
| Oohmedia Limited (OML) ORDINARY FULLY PAID |
Communication Services |
$771 |
Update - Notification of buy-back - OML
|
31 Mar 2026 8:22AM |
$0.880 |
$1.460 |
risen by
65.91%
|
|
| West African Resources Limited (WAF) ORDINARY FULLY PAID |
Materials |
$3,293 |
WAF 10-year gold production to average 533,000 oz per annum
|
31 Mar 2026 8:22AM |
$3.050 |
$2.880 |
fallen by
5.57%
|
|
WAF - Price-sensitive ASX Announcement
Full Release
Key Points
- WAF targets 533,000 oz annual gold production from 2026 to 2035.
- Production to peak at 596,000 oz in 2030.
- Sanbrado mine plan extended to 2036; Kiaka reduced to 2041.
- Extensive drilling programs to convert Inferred Mineral Resources.
- Sanbrado to average 250,000 oz annually; Kiaka to average 270,000 oz.
- Secondary crushing to increase throughput at Sanbrado and Kiaka.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$6,771 |
Update - Notification of buy-back - DNL
|
31 Mar 2026 8:22AM |
$3.110 |
$3.860 |
risen by
24.12%
|
|
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$5,307 |
Update - Notification of buy-back - WOR
|
31 Mar 2026 8:22AM |
$11.270 |
$10.830 |
fallen by
3.90%
|
|
| Reliance Worldwide Corporation Limited (RWC) ORDINARY FULLY PAID |
Industrials |
$2,850 |
Update - Notification of buy-back - RWC
|
31 Mar 2026 8:22AM |
$2.990 |
$3.810 |
risen by
27.42%
|
|
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$6,636 |
Update - Notification of buy-back - WHC
|
31 Mar 2026 8:22AM |
$9.840 |
$8.070 |
fallen by
17.99%
|
|
| Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID |
Health Care |
$6 |
New HMBD-002 Preclinical Data to be Presented at ASCO
|
31 Mar 2026 8:22AM |
$0.006 |
$0.004 |
fallen by
33.33%
|
|
| SiteMinder Limited (SDR) ORDINARY FULLY PAID |
Information Technology |
$1,090 |
Appendix 3Y - J Macdonald
|
31 Mar 2026 8:22AM |
$2.710 |
$3.850 |
risen by
42.07%
|
|
| Boom Logistics Limited (BOL) ORDINARY FULLY PAID |
Industrials |
$80 |
Update - Notification of buy-back - BOL
|
31 Mar 2026 8:22AM |
$1.670 |
$2.160 |
risen by
29.34%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$55,013 |
Update - Notification of buy-back - CSL
|
31 Mar 2026 8:22AM |
$140.820 |
$114.870 |
fallen by
18.43%
|
|
| Bayan Mining and Minerals Limited (BMM) ORDINARY FULLY PAID |
Materials |
$9 |
Bayan joins U.S. Defense Industrial Base Consortium
|
31 Mar 2026 8:22AM |
$0.070 |
$0.065 |
fallen by
7.14%
|
|
BMM - Price-sensitive ASX Announcement
Full Release
Key Points
- Bayan Mining and Minerals Limited joins U.S. Defense Industrial Base Consortium.
- Membership provides access to U.S. Department of War programs and non-dilutive funding.
- Bayan's Yttrium Upgrade patent supports U.S. critical mineral supply chains.
- DIBC membership aligns with U.S. efforts to secure domestic rare earth element supplies.
- Bayan enhances its profile and potential contributions to the U.S. defense ecosystem.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$91 |
Paradigm Achieves 50% Patient Dosing in Phase 3
|
31 Mar 2026 8:22AM |
$0.260 |
$0.155 |
fallen by
40.38%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Paradigm has achieved 50% patient enrolment in the global Phase 3 PARA_OA_012 trial.
- The trial evaluates injectable pentosan polysulfate sodium (iPPS) for knee osteoarthritis.
- Interim analysis results are expected in August 2026.
- The Phase 3 study design aligns with the earlier successful PARA_OA_008 trial.
- Improvements in trial methodology include real-time pain assessments and reduced placebo response.
- Paradigm aims to address both symptoms and underlying disease mechanisms of osteoarthritis.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Critical Resources Limited (CRR) ORDINARY FULLY PAID |
Materials |
$26 |
High-Grade Tungsten up to 42.6% WO3 as NZ Fieldwork Commence
|
31 Mar 2026 8:22AM |
$0.007 |
$0.008 |
risen by
14.29%
|
|
CRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Fieldwork targets gold and tungsten in Otago and Reefton regions.
- Croesus project reports tungsten grades up to 42.6% WO3.
- Mineralisation corridor extends over 5 km at Croesus.
- Lammerlaw project focuses on structural gold systems.
- Projects align with New Zealand's pro-investment reforms.
- Tungsten prices increased due to supply concerns.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Capral Limited (CAA) ORDINARY FULLY PAID |
Materials |
$176 |
Update - Notification of buy-back - CAA
|
31 Mar 2026 8:22AM |
$11.320 |
$11.070 |
fallen by
2.21%
|
|
| REA Group Ltd (REA) ORDINARY FULLY PAID |
Communication Services |
$17,475 |
Update - Notification of buy-back - REA
|
31 Mar 2026 8:22AM |
$151.000 |
$133.540 |
fallen by
11.56%
|
|
| PolarX Limited (PXX) ORDINARY FULLY PAID |
Materials |
$38 |
Strong silver assays from Ridgeline prospect at Humboldt
|
31 Mar 2026 8:21AM |
$0.016 |
$0.014 |
fallen by
12.50%
|
|
PXX - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong silver assays reported from Ridgeline prospect.
- Silver assays envelop the entire drill program with notable gold assays also present.
- Mineralisation extends over an 800-meter strike length and remains open.
- Located near substantial North American gold and silver mines.
- Plans for a major follow-up drilling program to explore further mineralisation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kogan.com Ltd (KGN) ORDINARY FULLY PAID |
Consumer Discretionary |
$405 |
Update - Notification of buy-back - KGN
|
31 Mar 2026 8:21AM |
$3.420 |
$4.250 |
risen by
24.27%
|
|
| Infini Resources Limited (I88) ORDINARY FULLY PAID |
Materials |
$12 |
Reynolds & Reitenbach Lake Maiden Drill Targets Finalised
|
31 Mar 2026 8:21AM |
$0.130 |
$0.115 |
fallen by
11.54%
|
|
I88 - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden diamond drilling program to test uranium targets at Reynolds & Reitenbach Lake.
- Program scheduled for mid-April 2026 with a minimum of 2,500m of drilling.
- High-grade uranium mineralization discovered at Titus Prospect.
- Drilling focuses on EM conductors, magnetic features, and uranium geochemical anomalies.
- Integration of datasets from 2025 exploration programs.
- Projects located on the eastern margin of the Athabasca Basin.
- Potential for basement-hosted uranium mineralization similar to Eagle Point.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Battery Age Minerals Ltd (BM8) ORDINARY FULLY PAID |
Materials |
$10 |
BM8 Expands USA Germanium-Gallium Project Landholding by 40%
|
31 Mar 2026 8:21AM |
$0.057 |
$0.046 |
fallen by
19.30%
|
|
BM8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Battery Age Minerals Ltd (ASX: BM8) expands US landholding by acquiring 51 additional claims.
- The Apex Project is now 40% larger, totaling 186 claims and approximately 3,728 acres.
- The project is located in the Beaver Dam Mountains, Utah, USA.
- Apex is near a high-grade germanium-gallium operation, important for semiconductors and satellite technology.
- The company integrates remote sensing technology to enhance exploration efforts.
- Battery Age focuses on critical minerals exploration and supply chain development in the US and EU.
- The acquisition aims to secure ground adjacent to the historic Apex Mine.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MetalsGrove Mining Ltd (MGA) ORDINARY FULLY PAID |
Materials |
$14 |
Up to 583 ppb Gold in Soils at Fifty-Five Prospect, Zuenoula
|
31 Mar 2026 8:21AM |
$0.100 |
$0.091 |
fallen by
9%
|
|
MGA - Price-sensitive ASX Announcement
Full Release
Key Points
- Seven gold prospects defined by soil sampling at Zuénoula, including Fifty-Five Prospect with a peak 583 ppb Au anomaly.
- Fifty-Five Prospect upgraded to top-priority target within a 3.3 km-long anomalous corridor.
- Central Prospect confirmed with a 148 ppb Au anomaly within a broader zone.
- Additional prospects identified: Eastern, Rouge, Konezra, and South-West.
- Infill and extensional sampling programs planned, supported by regolith mapping and LiDAR data.
- High-resolution LiDAR surveys assist in mapping structural features and artisanal activities.
- MetalsGrove is earning up to 80% interest in Zuénoula PR-750.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Technology One Limited (TNE) ORDINARY FULLY PAID |
Information Technology |
$9,451 |
Becoming a substantial holder
|
31 Mar 2026 8:21AM |
$26.470 |
$28.870 |
risen by
9.07%
|
|
| FMR Resources Limited (FMR) ORDINARY FULLY PAID |
Communication Services |
$20 |
Mineralised Stockwork Breccia and Porphyry at Target L
|
31 Mar 2026 8:21AM |
$0.275 |
$0.315 |
risen by
14.55%
|
|
FMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Drillhole 26LHDD073 completed at Target L to a depth of 1,068 meters.
- Broad zones of mineralised stockwork breccia and porphyry identified.
- Visible copper and molybdenite sulphides observed.
- Phase I drilling exceeded 5,000 meters, revealing mineralised systems.
- Future exploration will target the core of the Southern Porphyry system.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Patrys Limited (PAB) ORDINARY FULLY PAID |
Health Care |
$26 |
Investor Presentation - Broker Meets Biotech
|
31 Mar 2026 8:21AM |
$0.028 |
$0.039 |
risen by
39.29%
|
|
PAB - Price-sensitive ASX Announcement
Full Release
Key Points
- Patrys Limited focuses on the development of a proprietary injectable formulation of quetiapine for ICU settings.
- The company has a de-risked development pathway with a 3–5 year timeline and lower costs compared to traditional biotech approaches.
- Patrys leverages existing extensive clinical data of quetiapine to reduce regulatory and technical risks.
- The injectable formulation is expected to have immediate onset and is suitable for ICU, palliative, and aged care settings.
- The estimated serviceable addressable market for the delirium treatment is over US$2 billion annually.
- Patrys plans to use the FDA 505(b)(2) regulatory pathway for accelerated development.
- Key development milestones include ethics approval for Phase 1A in Q2 2026 and IND submission by Q4 2027.
- The company has a market capitalization of $15M with plans to partner or license the product.
- The board of directors comprises experts in ASX governance, biotech commercialization, and clinical trial operations.
- Injectable quetiapine aims to address the unmet need in delirium treatment with a faster control of symptoms and reduced hospital stay costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.